Affimed N.V. - Common Stock (AFMD)
Frequently Asked Questions About Affimed N.V. - Common Stock (AFMD)
How does Affimed contribute to the advancement of cancer research?
Affimed contributes significantly to the advancement of cancer research by developing novel immuno-oncology therapies that expand the understanding of immune-mediated tumor responses. Through collaborative research efforts, data sharing, and participation in scientific communities, Affimed is at the forefront of pushing innovative treatments for cancers, which can lead to new insights and approaches in the field.
How does Affimed engage with the investor community?
Affimed engages with the investor community through regular updates on clinical trial progress, financial performance, and strategic initiatives. The company participates in investor conferences, hosts earnings calls, and publishes press releases to maintain transparency and foster relationships with stakeholders. By actively communicating its vision and achievements, Affimed aims to build trust and support among investors.
How does Affimed ensure patient safety in clinical trials?
Affimed prioritizes patient safety in all its clinical trial protocols by adhering to strict regulatory standards and ethical guidelines. The company conducts thorough risk assessments and closely monitors participant health throughout the study. Adverse events are reported in real-time to regulatory authorities and are thoroughly investigated to ensure the safety and well-being of trial participants.
How does Affimed handle regulatory approvals?
Affimed collaborates closely with regulatory authorities, including the FDA and EMA, to ensure compliance with the necessary guidelines throughout product development. The company submits data from its clinical trials to obtain investigational new drug (IND) applications and prepares for eventual marketing authorization applications. Affimed’s regulatory team is experienced and works diligently to navigate the complex pathways for approval, enabling timely access to new therapies for patients.
How does Affimed's bispecific antibody technology work?
Affimed’s bispecific antibody technology works by simultaneously binding two different targets on cells within the immune system and cancer cells. This dual-targeting mechanism enhances the immune system's ability to recognize and destroy malignant cells. By bridging the immune effector cells and cancer cells, Affimed's antibodies activate a robust immune response that can lead to better therapeutic outcomes.
Is Affimed publicly traded?
Yes, Affimed N.V. is publicly traded on the NASDAQ under the ticker symbol 'AFMD.' The company went public in 2018, allowing it to access capital markets to fund its ongoing clinical trials and research initiatives. Being publicly traded provides Affimed with visibility within the investment community, which can facilitate strategic partnerships and business development.
What are Affimed's future plans?
Affimed aims to expand its pipeline of bispecific antibodies while continuing to advance its lead candidates through clinical trials. The company also plans to explore new therapeutic combinations and indications, enhancing its position in the immuno-oncology space. Future partnerships and collaborations are also part of Affimed's strategy to accelerate development and bring innovative therapies to market more swiftly.
What challenges does Affimed face in the biopharmaceutical industry?
Like many biopharmaceutical companies, Affimed faces challenges such as regulatory hurdles, competition in the crowded oncology market, and the high costs associated with bringing a drug to market. Additionally, securing funding for ongoing research and development amidst fluctuating market conditions can present obstacles. However, the company’s innovative approach and strategic partnerships help navigate these challenges effectively.
What differentiates Affimed from other biopharmaceutical companies?
What differentiates Affimed from other biopharmaceutical companies is its proprietary ROCK platform, which enables the rapid design and development of bispecific antibodies. This unique technology allows Affimed to create novel therapies that specifically activate and engage immune cells against tumors. Additionally, the company has a strong focus on collaboration, leveraging partnerships to enhance its innovation and accelerate product development.
What does Affimed N.V. do?
Affimed N.V. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. The company leverages its proprietary platform to create innovative bispecific antibodies that engage the immune system to target and destroy cancer cells. By harnessing the power of the immune system, Affimed aims to provide more effective treatments for various cancers, improving patient outcomes.
What is Affimed's mission?
Affimed’s mission is to revolutionize cancer treatment by developing groundbreaking immuno-oncology therapies that empower the immune system to fight cancer. The company strives to deliver innovative, effective, and safe treatments that improve patient outcomes and enhance quality of life for cancer patients globally. This mission drives its research, partnerships, and clinical focus.
What is the lead product candidate of Affimed?
Affimed's lead product candidate is AFM13, which is designed to treat CD30-positive lymphomas. This bispecific antibody aims to recruit and activate the body’s immune cells to attack cancer cells expressing CD30. AFM13 has advanced into late-stage clinical trials, and the company is investigating its potential in both monotherapy and combination treatments.
What is the status of Affimed's clinical trials?
Affimed's clinical trials are ongoing, with several candidates at various stages of development. The company has advanced its lead candidates through early-phase clinical trials and is actively working on multiple trials assessing safety, efficacy, and optimal dosing. Regular updates on trial outcomes and progress are provided to investors and stakeholders to ensure transparency and engagement.
What role does immuno-oncology play in Affimed's mission?
Immuno-oncology is central to Affimed's mission to revolutionize cancer treatment. The company focuses on harnessing the body’s immune system to fight cancer more effectively compared to traditional therapies. Affimed believes that immuno-oncology represents a paradigm shift in how cancers are treated, enabling the development of therapies that can lead to more durable responses with fewer side effects.
What strategic partnerships has Affimed formed?
Affimed has established several strategic partnerships with leading biotechnology and pharmaceutical companies to advance its research and development efforts. These collaborations often focus on combining Affimed's innovative therapies with other treatments to enhance effectiveness, leverage shared resources, and expedite development timelines. Notably, the company has partnered with global leaders to broaden its reach and amplify its impact in immuno-oncology.
What therapeutic areas does Affimed target?
Affimed primarily targets hematological cancers, including lymphomas and leukemias, where the need for effective therapies remains significant. The company also explores opportunities in solid tumors, broadening its focus to address a wider spectrum of malignancies. This strategy aligns with the increasing demand for innovative approaches in treating various cancer types.
What types of therapies does Affimed develop?
Affimed develops bispecific antibodies designed to engage and activate the immune system to target cancer cells. These therapies aim to enhance the body’s natural immune response against tumors. The company’s lead candidates target a variety of cancers, particularly hematological malignancies, and are designed to be more effective and less toxic than traditional cancer treatments.
When was Affimed N.V. founded?
Affimed N.V. was founded in 2000. Since its inception, the company has been dedicated to advancing immuno-oncology research and has developed a robust pipeline of therapeutic candidates. Over the years, Affimed has grown significantly, attracting investments and partnerships to accelerate its product development and clinical trials.
Where is Affimed N.V. headquartered?
Affimed N.V. is headquartered in Heidelberg, Germany. This location is strategically chosen to be close to key research institutions and biotech hubs, reflecting the company's commitment to innovation in cancer therapy development. In addition to its headquarters, Affimed has operations in the United States to enhance its reach and collaboration in the biotech industry.
Who are the key leadership team members at Affimed?
Affimed's leadership team comprises experienced professionals from the biotechnology and pharmaceutical sectors. The executive team includes individuals with extensive expertise in drug development, regulatory affairs, and commercialization. The board of directors includes distinguished members with backgrounds in finance, research, and corporate governance, providing guidance and strategic oversight for the company's growth.
What is the current price of Affimed N.V. - Common Stock?
The current price of Affimed N.V. - Common Stock is 0.6320
When was Affimed N.V. - Common Stock last traded?
The last trade of Affimed N.V. - Common Stock was at 4:00 pm EDT on April 3rd, 2025
What is the market capitalization of Affimed N.V. - Common Stock?
The market capitalization of Affimed N.V. - Common Stock is 9.62M
How many shares of Affimed N.V. - Common Stock are outstanding?
Affimed N.V. - Common Stock has 15.23M shares outstanding.